Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout

Author： Schumacher Jr   H Ralph  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.14, Iss.7, 2005-07, pp. : 893-903

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics, Pharmacodynamics and Safety of Febuxostat, a Non-Purine Selective Inhibitor of Xanthine Oxidase, in a Dose Escalation Study in Healthy Subjects

By Khosravan Reza   Grabowski Brian A.   Wu Jing-Tao   Joseph-Ridge Nancy   Vernillet Laurent  

Clinical Pharmacokinetics, Vol. 45, Iss. 8, 2006-01 ,pp. : 821-841

Adis International

Access to resources Recommend Favorite

Febuxostat for the Management of Hyperuricaemia in Patients with Gout: A NICE Single Technology Appraisal

By Stevenson Matt   Pandor Abdullah  

PharmacoEconomics, Vol. 29, Iss. 2, 2011-02 ,pp. : 133-140

Adis International

Access to resources Recommend Favorite

Xanthine Oxidase Inhibitor Febuxostat as a Novel Agent Postulated to Act Against Vascular Inflammation

By  

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Vol. 12, Iss. 1, 2013-03 ,pp. : 94-99

Bentham Science Publishers

Access to resources Recommend Favorite

Augmenting the Xanthine Oxidase Inhibitory Activity of Febuxostat by its Structural Modification

By  

Letters in Drug Design & Discovery, Vol. 11, Iss. 2, 2014-02 ,pp. : 207-210

Bentham Science Publishers

Access to resources Recommend Favorite

Overview of Hyperuricaemia and Gout

By  

Current Pharmaceutical Design, Vol. 11, Iss. 32, 2005-12 ,pp. : 4117-4124

Bentham Science Publishers

Access to resources Recommend Favorite